QICR 2024

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

Quality, Innovation, and Corporate Responsibility Report 2023—2024

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILIT Y

1

Message from the CEO

Table of Contents

About Myriad Genetics 5 6 7

Mission, vision, and values Our products and who we serve Supporting patient care

Quality 10 Operational excellence 11 Quality management system 12 Ethical marketing 12 Responsible supply chain management

Innovation 14 15 16 17 18

Advancements in R&D Product innovation Labs of the future Sharing data Partnerships

Corporate responsibility 20 23 27 28

Responsible governance People Sustainability Community

About this report Quality, innovation, and corporate responsibility are at the heart of what we do at Myriad Genetics. This report contains disclosures relevant to the Sustainability Accounting Standards Board (SASB) standards related to Healthcare Delivery, Biotechnology and Pharmaceuticals. Our greenhouse gas (GHG) emissions reporting aligns with the GHG Protocol Corporate Standard in an effort to provide consistency and transparency. This report covers information on our operations from January 1, 2023, through September 30, 2024 (the “Reporting Period”), unless stated otherwise.

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILIT Y

Message from the CEO Dear Stakeholders, I’m pleased to introduce our Quality, Innovation, and Corporate Responsibility Report.

In concert with our mission to advance health and well-being for all, we continue to execute our long-term strategic growth plan, driving sustained progress and impact.

As we look to the future, our engagement with the communities we serve and our role as a responsible corporate partner has never been more important. As a leader in genetic testing and precision medicine, we recognize the important role we play in advancing health equity and paving the way for more inclusive patient care. We do this through product innovation, research and clinical trials, and

advocacy efforts to make genetic testing available and accessible for all patients.

We achieved significant milestones in building our enterprise-wide infrastructure and capabilities with our state-of-the-art Labs of the Future. We completed the building of our new research and innovation center in South San Francisco, California and our new laboratory facility in Salt Lake City, Utah.

These new facilities enable us to bring new sequencing capabilities powered by advanced automation and robust analytics to ultimately yield improved workflows, faster turnaround times, and a better experience for healthcare providers and patients.

We are excited about the evolution of our product portfolio. We introduced our expanded

carrier screen, Foresight Universal® Plus, added Folate Receptor Alpha (FRα) to our Precise OncologySolutions® portfolio and introduced our Breast Cancer Risk Assessment (BCRA) program, which is designed to enable earlier detection. We incorporated breast density into MyRisk with RiskScore using Tyrer-Cuzick version 8 (TCv8) to provide patients and providers with a more comprehensive look at their fiveyear and remaining lifetime risk for breast cancer. For Prolaris®, we integrated Absolute Risk Reduction (ARR) into the Prolaris prostate cancer prognostic test to help patients and providers make personalized treatment decisions regarding hormone therapy. We look forward to the future launch of our multiple prenatal screen, FirstGene®, and our comprehensive genomic panel, Precise® Liquid.

I offer my sincere appreciation to our employees, customers, partners and the entire healthcare community for their continued enthusiasm and commitment to advancing genetic testing and precision medicine.

Together, we are making genetic testing more accessible, helping patients take more control of their health, and enabling providers to better prevent and treat disease.

I am grateful to our shareholders for their confidence in us and in our company. Your partnership, collaboration, and support strongly position us for enduring success as we work diligently to deliver on our mission.

Paul J. Diaz President and CEO

“ As a leader in genetic testing and precision medicine, we recognize the important role we play in advancing health equity and paving the way for more equitable and inclusive patient care.”

3

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

About Myriad Genetics Mission, vision, and values Our products and who we serve Supporting patient care

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILIT Y

4

MYRIAD GENETICS QICR REPORT 2023—2024

Our mission We advance health and well-being for all, empowering every individual by revealing the answers inside each of us.

MESSAGE FROM THE CEO

Our history We develop and offer tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. We were founded in 1991, 10 years before the human genome was sequenced. Our scientists have contributed to breakthroughs that have revolutionized the diagnosis and treatment of a number of diseases, including various cancers.

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILIT Y

Our values Collaborative

Our vision As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health and enable healthcare providers to better detect, treat and prevent disease.

ABOUT MYRIAD

We contribute to a greater cause and partner to achieve shared goals.

Caring We work in service of our patients and healthcare providers, defining our success through theirs.

Innovative We lead with a bold, imaginative, and purposedriven approach.

Inclusive We seek missing perspectives and strive to make all feel like they belong.

Committed We’re driven by challenges standing in the way of progress and remain diligent, determined, and accountable to embrace change.

5

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

Our products and who we serve

ABOUT MYRIAD

QUALIT Y

PATIENTS & THEIR PROVIDERS People with cancer

INNOVATION

CORPORATE RESPONSIBILIT Y

WHAT MYRIAD DELIVERS Diagnostic insight with clear clinical utility, including genetic insights that help clinicians determine the best treatment options • Germline BRCA1/2 mutations helping clinicians determine who may be eligible for certain targeted therapies • HRD status for ovarian cancer patients that can help providers determine the potential benefit of PARP inhibitor therapy • Clinically proven, objective information about prostate cancer’s behavior with traditional diagnostic tools like PSA and Gleason score • Pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors

Oncology

Women’s health

Pharmacogenomics

Clarifying cancer treatment with genetic insights and companion tests that are designed to work with corresponding treatments.

Delivering best-in-class genetic insights for women of all ancestries that assess cancer risk and offer prenatal solutions.

Giving healthcare providers insights on how genes may affect medication outcomes to treat depression, anxiety, ADHD, and other mental health conditions.

People at a high risk for cancer

Hereditary cancer testing, telling patients of their lifetime risk of developing certain cancers

Expectant parents

• Expanded carrier screening for all patients, regardless of ancestry • Carrier screening that helps couples understand if they are at risk of passing serious inherited conditions to their children • Prenatal screening delivering early genetic insights into a baby’s development • Predicted fetal sex as early as six weeks into pregnancy

Health equity The science we do is, by its very nature, inclusive. By improving the sensitivity of genetic assays and using powerful approaches to biostatistics, we are broadening access to genetic testing to all patient populations and communities, regardless of individuals’ socioeconomic status, ethnicity, body mass index or other characteristics.

People with mental health conditions like depression, anxiety, ADHD and others

Genetic test that analyzes how a patient’s genes may affect medication outcomes

6

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

Supporting patient care We offer services designed to expand access, including translation services to aid those whose first language is not English and telephone services for patients located in remote areas.

Genetic counselors Our team of Board-certified and licensed Genetic Counselors (GCs) guide patients through the testing process and interpret results in conjunction with their caregiving team. We offer patients comprehensive resources on our website, including “Genetic Testing 101,” answers to frequently asked questions, and detailed information about our

100+ Genetic Counselors

products. Many of our GCs are native Spanish speakers, and we aim to actively recruit GCs for our team who can speak one or more of the languages our patients speak.

We have relationships with several academic institutions engaged in training the next generation of GCs. Over the years, this has included the University of Utah, where our own GCs contribute to the training of students, and the Genetic Counselor program at Xavier University. We offer a summer rotation program available to students enrolled in Genetic Counselor training programs.

1,000+ Patients guided by our GCs each week

ABOUT MYRIAD

QUALIT Y

Our promise We support our MyRisk® patients throughout their lives by providing the latest data, updates, and new discoveries about their genetic information. If we develop new insights about a particular gene or relevant information emerges after a patient’s test, we strive to communicate these findings to the patient and their healthcare team, empowering them to take appropriate action.

INNOVATION

CORPORATE RESPONSIBILIT Y

7

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILIT Y

Affordability Price and billing transparency

Patient assistance and affordability

We believe in pricing and billing transparency. A team of approximately 300 employees is dedicated to working with commercial and government payers in the areas of prior authorization, billing, medical policy, and reimbursement.

Patient account teams proactively and reactively communicate with patients regarding their insurance coverage and bills, including estimates of out-of-pocket costs and direct-pay options.

We are committed to improving overall healthcare quality and increasing access to diagnostic testing for those in need by offering robust financial assistance. If patients are uninsured, underinsured, have restrictive policies that won’t fully cover our services, have high deductibles, and/or otherwise need additional financial support, we offer a direct pay option for some of our tests. Additionally, we will work with these patients to determine if they qualify for financial assistance.

We’ve developed new solutions to address patient and provider expectations on price transparency and affordability for our prenatal and hereditary cancer tests. We collaborate with patient advocacy and support organizations where we believe we can make a positive difference in addressing complex health challenges, provide education about diagnostic testing, and improve patients’ quality of life.

$51.3M+ in financial support to patients.1

T he financial support provided relates to the value of the tests we offered at a discount or for free through the reporting period outlined in this report.

1

For more information on our financial assistance programs, please visit: myriad.com/affordability/

8

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

Quality Operational excellence Quality management system Ethical marketing Responsible supply chain management

ABOUT MYRIAD

QUALITY

INNOVATION

CORPORATE RESPONSIBILIT Y

9

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

ABOUT MYRIAD

QUALITY

INNOVATION

CORPORATE RESPONSIBILIT Y

Operational excellence We are committed to operational excellence in our processes and products. Our people are empowered to find responsible solutions and to go above and beyond for our patients and healthcare providers. This spirit is reflected in our continued growth, high customer satisfaction ratings, and breakthrough innovations that improve people’s lives.

Winning culture

Customer service

Perception

Efficiency & productivity

84%

88%

72

70%

of our team rate Myriad as a “Great Place To Work”

1.1M

genetic tests performed

These numbers are accurate as of September 30, 2024.

samples processed within what we believe are industry-leading turn around times to support providers making treatment decisions

2,708 employees

Net Promoter Score among current Myriad providers who use our testing portfolio (through July 2024)

increase in cases processed per customer service representative since 2021

53.5K

actively ordering healthcare providers

10

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

QUALITY

INNOVATION

CORPORATE RESPONSIBILIT Y

Quality management system Myriad has developed and implemented a Quality Management System (QMS) in order to document the company’s best business practices, to ensure consistency in device manufacturing, and patienttesting services that meet regulatory and customer requirements. Our QMS is outlined in an established quality manual, which includes our quality policy.

Our laboratories are CLIA-certified and accredited by the College of American Pathologists (CAP), which ensures that test results meet or exceed the industry standard. Select laboratories are certified to international standards including ISO 13485 and ISO 15189.

Where applicable, our laboratories maintain compliance programs required of medical device manufacturers including the Food and Drug Administration (FDA) Quality System Regulation (QSR) as defined in 21 CFR 820 and associated international regulations.

Our management team establishes measurable quality objectives and key indicators of quality that support our approach in achieving the quality policy and reflect activities that are critical to patient testing performance. We have established a program to determine, collect, and analyze appropriate data to demonstrate the suitability and effectiveness of the established QMS. The program and data collected are used to monitor process and product quality, to identify and resolve issues, and to identify opportunities to improve the effectiveness of the QMS. All employees receive training on the QMS, upon hire, before assuming their responsibilities, and at defined intervals. Training is tailored to the relevance and importance of their roles in achieving quality objectives and meeting specific clinical laboratory regulatory requirements.

We have implemented a Corrective and Preventive Action (CAPA) program that defines the requirements for reviewing, determining, and evaluating nonconformities and, where appropriate, taking actions to prevent recurrence.

We currently have no known events that would necessitate FDA notification per the Medical Devise Reporting (MDR) requirement within the Reporting Period.

11

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

QUALITY

INNOVATION

CORPORATE RESPONSIBILIT Y

Responsible supply chain management

Ethical marketing To ensure fair balance and verify that marketing claims are truthful, cross-functional teams regularly review and update marketing messages and materials for accuracy. These teams include representatives from medical affairs, laboratory, legal, compliance, payer markets, and other groups.

All promotional materials aim to meet the following criteria: •A ll claims are technically accurate and sufficiently substantiated by supporting data.

•M aterials comply with applicable laws and regulations.

•C ommunications can be fully understood by the intended audience.

•M aterials meet a high standard for quality and clarity.

As a provider of critical healthcare and medical products and services, we strive to manage our suppliers and supply chain to the highest standards of quality and in compliance with all applicable laws and regulations. When vendors make product changes, we collaborate with our research and development (R&D) teams and other internal resources to ensure these changes meet our performance and product standards. If required, we seek FDA approval for these changes.

Supplier Code of Conduct If suppliers want to change materials or change production locations, they must notify us to ensure that all regulations and expectations are fully met. In 2023, we introduced our Supplier Code of Conduct, outlining expectations for our suppliers that go beyond price and quality. This ensures they operate in alignment with our values and performance standards, including: • Ethics: Anti-bribery and anti-corruption, fair competition, conflict of interest, data privacy and security, confidentiality • Labor and human rights: Anti-slavery/anti-trafficking, child labor, inclusion and diversity, nondiscrimination, free choice, fair treatment, open communication • Health and safety: Worker protection, process safety, emergency preparedness and responses • Sustainability and environmental responsibility: Waste and emissions, spills and releases, resource use, reporting and data provision

12

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

Innovation Advancements in R&D Product innovation Labs of the future Data sharing Partnerships

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILIT Y

13

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILIT Y

14

Advancements in R&D As a company founded on innovation and scientific discovery, we continue to pave the way in genetic testing.

One example from the past year is our progress in developing our Molecular Residual Disease (MRD) test, which is designed to detect the presence of circulating tumor DNA (ctDNA) in the bloodstream.

Our Precise® MRD test, which we plan to launch commercially in 2026, is a tumor-informed, wholegenome-sequencing test that monitors hundreds to thousands of tumor-specific variants. This approach enables exceptional sensitivity and quantification of ctDNA in the blood of patients with cancer. The Precise MRD test will be used to monitor ctDNA levels throughout a cancer patient’s clinical care, starting immediately after diagnosis and continuing through treatment and surveillance.

Whole-genome sequencing is what makes our MRD assay different than many other tests. We start by profiling – with whole-genome sequencing – both the tumor and normal tissues. Then, the MRD assay identifies somatic variants, which are used to create a custom panel with 1,000 sites. Other MRD tests use exome sequencing, which results in fewer sites (typically about 16 sites).

In 2024, we announced that we have five research collaborations to study the use of MRD testing in breast cancer, with more on the way.

Myriad Precise MRD test

10x

Higher sensitivity: Detection at 10x lower tumor levels

100x

more of the genome explored

60x

More than 60x more targeted sites

Earlier

detection of recurrence

Data shown compares Myriad's Precise MRD test with statistics published by a leading competitor (Signatera).

Myriad was awarded three MRD-related patents by the United States Patent and Trademark Office in 2024 that support our MRD assay.

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILIT Y

Product innovation Our clinically differentiated products deliver value in real-world clinical settings by enabling early detection and better treatment decisions for providers and their patients.

Breast Cancer Risk Assessment (BCRA) program: Designed to enable earlier detection, we introduced our BCRA program to empower healthcare providers with our genetic testing and personal family history analysis to identify patients at elevated risk.

MyRisk Hereditary Cancer Test with RiskScore : We incorporated breast density using Tyrer-Cuzick version 8 (TCv8) to provide patients and providers with a more comprehensive look at their five-year and remaining lifetime risk for breast cancer.

MyRisk with RiskScore is the first breast cancer risk model that includes breast density, personal/family clinical history, and a polygenic risk score (PRS) based on genetically determined ancestry. ®

SneakPeek® In 2023, we announced that we reached a new milestone, delivering SneakPeek Early Gender DNA Test® results to one million consumers. Since 2015, SneakPeek has provided expectant families with an easy and convenient way to learn the sex of their baby as early as six weeks into pregnancy.

®

Prequel® Prenatal Screen: We published a study in Prenatal Diagnosis, demonstrating exceptional positive predictive value (PPV) for 22q11.2 microdeletion screening using our prenatal cell-free DNA (pcfDNA) screen, Prequel, which incorporates fetal fraction amplification.

Foresight® Carrier Screen: We added the Universal Plus Panel to our Foresight Carrier Screen. The panel includes 39 conditions and screens up to 272 genes associated with serious inherited conditions.

SneakPeek: We were awarded a patent for the SneakPeek SNAP® device, which is a push-button blood collection device for PCR-based fetal sex determination.

Precise Oncology: We added Folate Receptor Alpha (FRα) to our Precise Oncology Solutions® portfolio. The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer.

Prolaris® Prostate Cancer Prognostic Test: We integrated Absolute Risk Reduction (ARR) into the Prolaris prostate cancer prognostic test to help patients and providers make personalized treatment decisions regarding hormone therapy.

Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy (ADT) to radiation therapy (RT).

The GeneSight® Test: We included information in the GeneSight report about how a patient’s smoking status may impact their body’s metabolism of certain medications. Taking smoking status into consideration helps ensure the test provides an even more complete picture of patients’ potential outcomes with certain medications.

15

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILIT Y

Labs of the Future Our modernized laboratory facilities and robust commercial engine are examples of where our investments in automation and advanced technology are expected to yield improved workflows, faster turnaround times and reduced operating costs.

We achieved significant milestones in 2023 in building our enterprise-wide infrastructure and capabilities with our state-of-the-art Labs of the Future. We completed construction of our new research and innovation center in South San Francisco and our new laboratory facility in Salt Lake City. These new facilities will enable high-volume growth at significantly

lower costs with new sequencing capabilities powered by advanced automation and robust analytics.

In early 2024, we acquired select assets from Intermountain Precision Genomics (IPG) laboratory business, including the Precise Tumor® Test, the Precise® Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah. Following the acquisition, a cross-functional team led an effort to maintain Precise Tumor testing while moving laboratory equipment to our Salt Lake City facility, created a new laboratory information management system (LIMS), qualified equipment, validated the Precise Tumor assay and new LIMS at our Salt Lake City facility, and merged newly acquired talent into the Myriad family.

As a result of these efforts, our team began processing the first Precise Tumor patient samples in our Salt Lake City laboratory in late 2024.

We achieved significant milestones in 2023 when building our enterprise-wide infrastructure and capabilities with our state-of-the-art Labs of the Future.

16

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILIT Y

Sharing data We are committed to sharing our data for use in clinical care and scientific research.

Myriad Collaborative Research Registry Established in 2023, the Myriad Collaborative Research Registry™ (MCRR) includes new data across germline and tumor testing results from our cancer products on more than one million patients.

The MCRR is one of the largest pan-cancer registries freely available for research use and supports transparent clinical data sharing to advance the field. The MCRR currently contains de-identified research data across a broad list of cancer indications and includes genomic test data associated with family history, ethnicity, and clinical characteristics.

ClinVar

ClinVar, part of the National Institutes of Health, is a freely accessible, public archive of reports of human variations classified for diseases and drug responses, with supporting evidence.

We have shared data from our Women’s Health prenatal tests with ClinVar for many years; we started sharing clinically impactful hereditary cancer data with ClinVar in spring 2023.

Myriad continues to share data submissions with ClinVar quarterly, with a goal to contribute more than 10,000 clinically impactful variants annually.

Scientific publishing We have shared our expertise through hundreds of scientific publications to date. We have published nearly 90 manuscripts and poster presentations during the Reporting Period.

17

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILIT Y

Working together We announced several collaborations with other organizations designed to enhance our offerings and bring our services to larger numbers of patients.

Illumina

QIAGEN

Flatiron

Personalis

SimonMed® Imaging

We reached two significant milestones in our strategic partnership in 2023. The first qualified us to conduct prospective clinical trial testing using an investigationaluse-only test based on Illumina’s in-development IVD solution, the TruSight Oncology Comprehensive (TSO Comp) test. The second provides our support of Illumina’s partnerships with pharmaceutical companies to develop companion diagnostics on TSO Comp.

We signed a new master collaboration agreement to develop companion diagnostic tests in the field of cancer. The first collaboration is a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status.

We enabled physicians to order MyRisk Hereditary Cancer Test and view the results of the test directly in Flatiron’s cloud-based Electronic Medical Record (EMR) platform, OncoEMR®.

We entered into an agreement to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease (MRD).

Working to broaden access to genetic testing, we launched a new hereditary cancer assessment program that combines diagnostic imaging, patient education and genetic risk assessment utilizing MyRisk® with RiskScore®.

jscreen™

Onsite Women’s Health

We announced a strategic partnership that enables jscreen to deliver in-person genetic screenings using MyRisk with RiskScore and Foresight® Carrier Screen.

We combined MyRisk with RiskScore with Onsite’s mammography and breast ultrasound services to help more women understand their breast cancer risk.

18

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

Corporate responsibility Governance People Sustainability Community

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILITY

19

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

ABOUT MYRIAD

QUALIT Y

Responsible governance

INNOVATION

CORPORATE RESPONSIBILITY

Director diversity

50%

Board of Directors

of directors are diverse members

The Board of Directors (Board) considers its composition, diversity, capabilities, expertise, and experience when considering our business strategies, challenges, and opportunities.

Eight out of the nine board members, including the chair, are classified as “independent directors” as defined by The Nasdaq Stock Market LLC rules and 50% of our board members come from diverse gender, ethnic, and cultural backgrounds.

The Board holds primary responsibility for QICR oversight, with specific duties delegated to standing committees to support QICR development and execution.

We also have a management-level committee, comprised of leaders from across our organization, including from our human resources, commercial and laboratory operations, accounting, technology, legal and communications teams, who are actively involved in corporate responsibility matters. This committee advises on corporate responsibility and sustainable business practices.

20

There are four Board committees:

Director independence

Audit and Finance Committee (AFC)

Compensation and Human Capital Committee (CHCC)

• Risk management • I nformation and cybersecurity

• Leadership development and human capital, including DEI

• L egal and regulatory compliance

• Executive compensation and benefits

Nominating and Governance Committee (NGC)

• Our 2023 short-term incentive program which includes two nonfinancial metrics, employee engagement and customer net promoter score, in determining annual cash bonus amounts

• Corporate responsibility strategies, practices and initiatives • Corporate responsibility disclosures • Shareholder feedback and corporate governance

Research and Product Innovation Committee (RPIC) • Product research and development • Clinical development • Technical and commercial innovations

88%

of directors are independent

Director tenure

6.9 years is the average tenure. 50% of the directors have a tenure of less than 5 years.

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILITY

Governing policies

Risk management

Our Code of Conduct provides guidance on a range of key topics, including anonymous reporting of concerns, fair competition and antitrust, privacy and security, human rights and human trafficking, insider information, and conflict of interest. Our Corporate Governance Principles and Insider Trading Policy memorialize our corporate governance practices and insider trading policies and procedures.

Our Board has an active role, directly and through its committees, in the oversight of our risk management efforts. The Board and management regularly review information regarding the risks inherent in the operation of our businesses and our risk mitigation efforts. Each of the Board’s committees oversees the management of risks that are under each committee’s areas of responsibility.

For more information, visit investor.myriad.com/corporate-governance.

Myriad policies include:

•C orporate Code of Conduct

• Conflict of Interest Policy

• Myriad Quality Policy

•U nited States Compliance Guide on Interactions With Healthcare Professionals

• HIPAA Privacy and Security Policy

• Quality Management System (QMS)

• I nternational Compliance Guide on Interactions With Healthcare Professionals and Government Officials

• Business Continuity Plan

•C orporate Governance Principles

• Employee Manual

• Notice of Privacy Practices • Insider Trading Policy • Supplier Code of Conduct

• Quality Manual • Risk Management Policy • Corrective and Preventative Action Program (CAPA)

21

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

ABOUT MYRIAD

Ethics and compliance

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILITY

Privacy and security

Our Corporate Compliance team supports and enables good governance and business integrity in all we do.

The program’s structure is informed by guidance from federal enforcement agencies and has adapted over time to meet new challenges.

• audits and monitors operational activities with potential compliance ramifications.

The team:

• responds to employee questions and reports, including from the compliance hotline and the online reporting form.

• conducts annual Code of Conduct training with employee confirmations acknowledging their duty to observe the included guidelines.

• hosts an annual Corporate Compliance & Ethics Week, featuring educational presentations and live training opportunities.

• distributes a company-wide compliance survey to assess the level of awareness and understanding of ethical business practices.

• provides general and role-based compliance training.

• investigates allegations of compliance violations.

• presents periodic reports to executive leadership, the AFC, and the Board.

Our employees are strongly encouraged to ask questions and/or report concerns to their supervisor, the People Team, the Legal Department, the Corporate Compliance and Ethics personnel, privacy personnel, the compliance or privacy email boxes, the online reporting form or the compliance hotline.

We handle our patients’ sensitive and private genetic information with great care and security to ensure that it is used properly and is accessible only to authorized people.

We strive to comply with all applicable privacy laws and regulations, such as the Health Insurance Portability and Accountability Act (HIPAA), the California Consumer Privacy Act (CCPA) and the General Data Protection Regulation (GDPR), to the extent they apply to our business. We require all employees to participate in annual HIPAA and cybersecurity training.

We are not aware of any material violations of our Code of Conduct during the Reporting Period.

Ethics & Compliance contact information

Hotline number:

Online reporting form:

866.685.8668

MyriadHotline.com

In 2023, we obtained HiTRUST certification for our prenatal products, Foresight® and Prequel®, and retained certification for GeneSight®. This certification indicates that our product and ordering platforms for these products have met key regulations and industry-defined requirements and are appropriately managed for risk.

22

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILITY

People

Employee resource groups (ERGs)

Lifting others up

Our success comes from our people. Our People Team is dedicated to recruiting, developing and retaining our teammates so they can bring their best to work each day.

One way we support our teammates is through employee resource groups (ERGs). Our active ERG communities provide a safe space for teammates from shared backgrounds and their allies to connect, communicate and support each other.

This year, we introduced the Myriad HOPE (Helping Our People Endure) fund to help teammates in need of immediate financial assistance following an unforeseen challenge or personal hardship, such as repairs resulting from natural disaster or serious illness or injury, etc. The fund relies on support from Myriad and individual donations made by partners, employees, and the public.

Over the past two years, we have named several new leaders to our executive team—including our chief operating officer, chief legal officer, and chief financial officer. These leaders bring a wealth of healthcare industry experience to Myriad that will help position our company for continued innovation and growth.

Award-winning culture Myriad was recognized as one of “America’s Best Midsize Companies” in TIME Magazine in 2024, included in Fortune magazine’s 2023 Best Workplaces in Health Care list and also received the Great Place to Work® certification for 2023 and 2024. These certifications are based on what current employees say about their experience working at Myriad. All are a testament to our dynamic and diverse culture, where career development is prioritized, and all teammates have equal opportunity to grow and make a difference in our patients’ lives.

23

MESSAGE FROM THE CEO

MYRIAD GENETICS QICR REPORT 2023—2024

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILITY

Caring, belonging, and engagement Employee demographics Embracing multiple perspectives based on a rich variety of backgrounds, cultures, experiences, ethnicities, religions, visible and invisible disabilities, and other dimensions of diversity provides us with a strategic advantage. By creating a team that reflects the diversity of the customers we serve, we can develop vital products and identify solutions to the barriers

faced by many patients when accessing highquality healthcare and genetic testing.

We strive to be inclusive of all people, creating a shared sense of safety and belonging. We continually and regularly assess compensation programs to address any gender pay disparities in our workforce.

2,708 teammates strong Ethnicity

69.4%

8.7%

White

Hispanic or Latino

12.1%

6.2%

Asian

Black or African American

2.4% Other

1.2%

Not disclosed as of 9/30/2024

24

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

Employee engagement and retention

Employee health and safety

We measure and monitor feedback from our people in several ways, including an annual engagement survey.

Our various strategic initiatives improve our employee engagement score and reduce turnover. These initiatives include:

We take substantial measures to protect employees from unnecessary risks, hazardous materials and dangerous operating conditions. We strive to handle all chemical and biological waste according to all applicable laws, regulations and best practices.

We provide personal protective equipment — such as protective (and prescription, where needed) safety goggles, laboratory coats and gloves — to our laboratory employees.

• The Spark program, designed to offer professional development to high-potential teammates.

• Learning and development opportunities.

•K eeping our employees informed through quarterly all-hand meetings and weekly newsletters.

84%

In 2024, 84% of employees said Myriad is a great place to work — 27 percentage points higher than the typical U.S. company.

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILITY

25

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILITY

26

Benefits Myriad Genetics offers a total reward package that is competitive with the market, provides fairness, and rewards all teammates for performance that drives our mission, vision, and values. Specialized benefits include: • Access to Myriad Genetics full catalogue of tests

• Basic healthcare Medical, Dental, Vision + FSA/HSA Options

• Carrot (holistic family planning)

• 401k with matching contribution

• Telehealth (virtual medical advice)

• Life & AD&D Insurance

• Spring Health (mental wellness)

• Pet insurance

• MoveSpring Wellbeing Challenges

• Employee Stock Purchase Plan (ESPP)

• Employee Assistance Program • Volunteer Day • Generous Paid Time Off and Discretionary Time Off (exempt employees only) • Recognition and rewards programs

• Student Debt Program • Tuition Reimbursement • Paid parental leave • Identity protection & cyber insurance

Myriad offers employees a comprehensive package of health, retirement and well-being benefits.

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILITY

Sustainability

In 2023, we released an estimated 1,444

Minimizing our environmental impact on the world is consistent with our values.

While we believe that our environmental footprint is modest, we actively seek ways to reduce the impact we do have in a sustainable manner.

equivalent (MT CO2e) of Scope 1 and

The Myriad Green Team is a central pillar of our environmental efforts, engaging employees across our business in our activities and participating in events that benefit local communities.

For example, the Green Team participated in the International Coastal Clean-Up Day at the Great Salt Lake State Park, removing trash from our waterways and protecting marine ecosystems.

144.4 tons Since 2019 and through Sept. 30, 2024, we have recycled nearly 144.4 tons of plastic from our Salt Lake City laboratories, including almost 46.9 tons between January 1, 2023, and September 30, 2024.

and 3,100 metric tons of carbon dioxide Scope 2 emissions, respectively.

Across all our facilities, we have worked with our property owners to find opportunities to incorporate energy efficiency, water efficiency, and renewable energy generation.

and hybrid vehicles. We provide tax-free commuter benefits to teammates who commute to any Myriad location for work and encourage ride-sharing apps to reduce private car usage.

Tackling plastics in the laboratory

Sustainability efforts

One area of our environmental focus is the use of plastics in our laboratories. Samples, reagents and other materials involved in genetic test processing are stored and shipped in plastic containers.

Previously discarded into laboratory waste bins, the Green Team and laboratory staff developed a program to recycle used plastics, including pipette tip boxes, sample plates, reagent bottles and consumable labware, diverting them from landfills and incinerators.

Our new lab facilities include energy and water efficiency and environmental-friendly features. In fact, our new South San Francisco Nexus building is now a LEED Sliver certified facility.

These facilities are equipped with automated liquid handling and waste treatment capabilities, which reduce plastic waste and create a more environmentally sustainable laboratory. We have collaborated closely with construction and design teams to make buildings and landscaping more sustainable with more environmentally responsible and renewable materials.

Our carbon footprint We continue to explore ways to minimize our environmental impacts where economically and technically viable. We measure our energy usage across our campuses and report our Scope 1 and Scope 2 emissions. Energy and emissions data were captured for select buildings with the largest footprint and used to model emissions from our remaining operations where limited or no data was available.

At our major campuses in Salt Lake City and South San Francisco, we have electric vehicle charging stations available for electric

Looking ahead As we transform and grow, we recognize the opportunity to further integrate environmental performance, efficiency and sustainability into our operations. We plan to improve the data quality behind our environmental footprint assessment and provide additional public disclosures regarding our environmental performance to our stakeholders. We are actively exploring options for conducting this analysis in accordance with climate-relevant sustainability metrics.

27

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILITY

Community Through our philanthropic and community support, we strive to build greater value for patients, healthcare professionals, shareholders, and the communities where we live and work.

Elevating health equity In 2023, we became an official sponsor of March of Dimes, a leading and well-respected organization focused on improving the health of mothers and babies. Through this partnership, we have sponsored fundraising walks in four cities, community-based programs to support moms and babies, and a new doula program that will encourage the use of doulas in underserved communities.

Building an inclusive community Our teammates hosted a fundraiser to support Transform Cincy, a local nonprofit providing free wardrobes and resources to transgender and gender non-conforming youth. Teammates participated in and sponsored Cincinnati Pride events, honoring the LGBTQ+ community and bolstering our commitment to mental health care.

Supporting mental health Teammates at our Mason, Ohio office participated in the NAMI SW Ohio Walk. The team raised funds through employee-led events, including Grilled Cheese Day, bake sale, and silent auction.

28

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILITY

Community, continued

Feeding the hungry Teammates in Mason, Ohio organized a canned food drive to support the Mason Food Pantry. The team collected items to donate by holding a holiday decorating contest. To vote, employees had to bring a canned-food item to donate.

Organizations we support • National Medical Association

• National Alliance for Disparities in Patient Health (NADPH)

• National Alliance on Mental illness

• National Hispanic Medical Association (NHMA)

• Tigerlily Foundation

• Mental Health America (MHA)

• BreastCancer.org

• Depression Bipolar Support Alliance (DBS)

• North Carolina Central University

• Families for Depression Awareness (FFDA)

• Zero Prostate Cancer

• American Association of Nurse Practitioners (AANP)

• African American Male Wellness Agency (AAMWA)

• American Academy of Family Physicians (AAFP)

• Black Physicians of Utah (BPOU)

• American Psychiatric Association Foundation (APA)

• Arab Society of Genetic Counselors (ASGC)

• National Council for Mental Wellbeing (NATCON)

29

MYRIAD GENETICS QICR REPORT 2023—2024

MESSAGE FROM THE CEO

ABOUT MYRIAD

Forward-looking statements and other matters This report contains forward-looking statements that reflect Myriad’s views about future events as of the date of this report, including information about products, partnerships, quality programs, and its environmental, social, governance and corporate responsibility goals and related policies, programs and initiatives. Words such as “expect,” “could,” “would,” “believe,” “plan, “seek,” “will,” “positions,” “strategies,” “opportunities,” “target” and similar expressions and variations thereof identify forward-looking statements, which are not historical in nature. These statements are not guarantees of future conduct, policy or results and are subject to certain risks, uncertainties, assumptions and other factors, many of which are beyond our control and difficult to predict. Such factors include those risks described in our filings with the United States Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Consequently, the actual results or conduct of our activities, including the development, implementation or continuation of any policy, program or initiative discussed or forecasted in this report, may differ materially in the future. Except as required by applicable law, we disclaim any obligation to update any statements in this report should circumstances or management’s expectations, opinions or beliefs change. This report also contains quality, innovation, corporate responsibility and other data that have not been audited by a third party.

As used in this report, the terms “Myriad Genetics,” “Myriad,” “company,” “our,” “we” and “us” may refer to Myriad Genetics, Inc. and/or one or more of its consolidated subsidiaries. All of these terms are used for convenience only and are not intended as a precise description of any of these separate entities. Any comments or feedback on this report can be directed to qicr@myriad.com.

This report contains quantitative data and qualitative information regarding these topics where available for Myriad as a whole, covering the 21-month period ending September 30, 2024, except as noted otherwise.

QUALIT Y

INNOVATION

CORPORATE RESPONSIBILITY

30

Myriad Genetics Corporate Headquarters 322 North 2200 West Salt Lake City, UT 84116 CORPORATE PHONE: (801) 584-3600